The importance of RT-qPCR primer design for the detection of siRNA-mediated mRNA silencing by Herbert, Mike et al.
SHORT REPORT Open Access
The importance of RT-qPCR primer design for the
detection of siRNA-mediated mRNA silencing
Mike Herbert
1,3, Natacha Coppieters
1,4, Annette Lasham
1,5, Helen Cao
1,6 and Glen Reid
1,2,7*
Abstract
Background: The use of RNAi to analyse gene function in vitro is now widely applied in biological research.
However, several difficulties are associated with its use in vivo, mainly relating to inefficient delivery and non-
specific effects of short RNA duplexes in animal models. The latter can lead to false positive results when real-time
RT-qPCR alone is used to measure target mRNA knockdown.
Findings: We observed that detection of an apparent siRNA-mediated knockdown in vivo was dependent on the
primers used for real-time RT-qPCR measurement of the target mRNA. Two siRNAs specific for RRM1 with
equivalent activity in vitro were administered to A549 xenografts via intratumoural injection. In each case, apparent
knockdown of RRM1 mRNA was observed only when the primer pair used in RT-qPCR flanked the siRNA cleavage
site. This false-positive result was found to result from co-purified siRNA interfering with both reverse transcription
and qPCR.
Conclusions: Our data suggest that using primers flanking the siRNA-mediated cleavage site in RT-qPCR-based
measurements of mRNA knockdown in vivo can lead to false positive results. This is particularly relevant where high
concentrations of siRNA are introduced, particularly via intratumoural injection, as the siRNA may be co-purified with
the RNA and interfere with downstream enzymatic steps. Based on these results, using primers flanking the siRNA
target site should be avoided when measuring knockdown of target mRNA by real-time RT-qPCR.
Background
The use of RNAi to inhibit gene expression has revolutio-
nised medical research and has great therapeutic poten-
tial. However, inefficient siRNA delivery and off-target
effects hamper translation from in vitro experiments to
in vivo research and clinic application. Many approaches
to improve delivery are under investigation, such as the
use of localised delivery by direct injection and topical
application, and intravenous administration for systemic
delivery [1-3]. Despite the growing use of RNAi in vivo,
very few studies include data to confirm that the
observed effects of the siRNA are due to an RNAi-
mediated mRNA cleavage mechanism rather than non-
specific events.
The importance of confirming that mRNA reduction
following siRNA administration has occurred via RNAi-
mediated events is highlighted by recent studies reporting
the contribution of the innate immune system to apparent
in vivo knockdown of target mRNAs. The double-stranded
nature of siRNA imparts the ability to trigger an innate
immune response via the activation of Toll-like receptors
(TLR 3, 7 and 8) and binding to proteins such as retinoic
acid inducible gene 1 (RIG-1) [4,5]. These interactions
may cause a down-regulation of gene expression that can
be falsely attributed to a sequence-specific RNAi-medi-
tated event. Together this suggests that many of the
reports of in vivo efficacy of siRNAs can be explained by a
general down-regulation of transcription that is stimulated
by the double-stranded RNA structure of siRNA without
involving RNAi, especially in the absence of corroborating
evidence [6,7].
More recently Holmes et al. found that the 3’fragment
produced following siRNA-mediated cleavage of certain
target mRNAs can persist and that this can compromise
RT-qPCR-mediated detection of knockdown [8], similar
to the findings of others [9,10] suggesting that incom-
plete degradation of mRNA cleavage fragments can result
in inaccurate determination of knockdown by RT-qPCR.
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as a means to avoid this problem. Here we show that this
approach can lead to artefactual results when siRNAs are
used in certain in vivo s e t t i n g s ,a ss i R N A sc o - p u r i f i e d
with total RNA can interfere with downstream analysis,
in some cases leading to false positive results.
Materials and methods
Cell Culture
The A549 (human non-small cell lung cancer) and
Hepa 1-6 (mouse hepatoma) cell lines used in this
study were obtained from ATCC and were grown in
RPMI medium supplemented with 10% heat-inactivated
fetal bovine serum (FBS) (both from Invitrogen Cor-
poration, Carlsbad, CA), at 37°C in humidified air with
5% CO2.
siRNAs and transfection
The siRNAs and Lipofectamine RNAiMax were from
Invitrogen. The siRNA sequences are listed in Table 1.
Transfection was carried out as described previously
[11], using Lipofectamine RNAiMax (at a concentration
of 0.8 μL per mL) and cells at a final density of 5 × 10
3
per cm
2. After overnight incubation, transfection med-
ium was replaced with RPMI containing 10% FBS, and
cells were analyzed at indicated time points.
RT-qPCR
RNA was isolated using the PureLink 96 RNA Purifica-
tion system (Invitrogen), with an additional Trizol (Invi-
trogen) extraction for in vivo samples, quantified via
spectrophotometry using a Nanodrop (Thermo Scienti-
fic), and first-strand cDNA synthesised using Superscript
III polymerase (Invitrogen), as described [12]. For real-
time qPCR, the cDNA was diluted 1:4 in 10 mM Tris
pH 7.0, with reactions carried out on a LightCycler 480
(Roche) using SybrGreen I Master mix (Roche) and
gene-specific primers at 180 nM (Table 1) in 384 white
multi-well plates [12]. Primer sets specific to different
regions were used to measure RRM1 mRNA, as depicted
in Figure 1. Melting curve analysis was performed to
c o n f i r mt h a tas i n g l ep r o d u c tw a sb e i n ga m p l i f i e d ,a n d
the products were run out on agarose gels to confirm
their predicted amplicon size (data not shown). For
competition experiments, the indicated concentrations
of siRNAs or RNA oligonucleotides were added to the
RNA or cDNA templates prior to reverse transcription
or PCR, respectively. Levels of RRM1 mRNA were nor-
malised to the reference genes LMNA or HMBS,w i t h
ApoB normalised to Polr2a for mouse samples, and rela-
tive change in mRNA levels following treatment with
specific or control siRNA was calculated from triplicate
technical replicates of each using the 2
-ΔΔCt method
Table 1 Sequences of siRNAs, RNA oligos and RT-qPCR primers used in the study
siRNAs
Name Passenger strand Guide strand
RRM1-2 CCCAGUUACUGAAUAAGCAGAUCUU AAGAUCUGCUUAUUCAGUAACUGGGCU
RRM1-3
§ GCAAACUCACUAGUAUGCACUUCUA UAGAAGUGCAUACUAGUGAGUUUGCCU
ApoB-1
§ GUCAUCACACUGAAUACCAAU AUUGGUAUUCAGUGUGAUGAmC*mA*C
ApoB1 mm control GUGAUCAGACUCAAUACGAAU AUUCGUAUUGAGUCUGAUCAmC*mA*C
81-control AAGAUCUGCUUAUUCAGUAACUGGG CCCAGUUACUGAAUAAGCAGAUCUU
Single-strand RNA oligos
Name Sequence
RRM1-3-sense GCAAACUCACUAGUAUGCACUUCUA
RRM1-3-antisense UAGAAGUGCAUACUAGUGAGUUUGCCU
qPCR Primers
Target Forward Reverse
RRM1(A)
† TGGATCAAGGTGGGAACAAG CGACGAGAAGGAAAGGACAC
RRM1(B)
† GGTACAAGGTCTGGCAGATGCT TTCCAGTGTCGACCGAAGGT
RRM1(C)
† CATCCACATTGCTGAGCCTAAC GGGTCAGAAGTTTGGGACGAA
ApoB1 site AGCCATGGGCAACTTTACCT AAAGGAAATGGGCAACGATA
ApoB external GGCACTGTGGGTCTGGAT TTCTTCTCTGGAGGGGACTG
HMBS AGCCTGTTTACCAAGGAGCT GAGTGAACAACCAGGTCCAC
LMNA TGAGGCCAAGAAGCAACTTCA CTCATGACGGCGCTTGGT
Polr2a TTACTCCCCTGCATGGTCTC TGGGAGACATAGCACCACCT
* Represents phosphorothioate linkages between nucleotides in the siRNA backbone.
† Targets RRM1-A, B and C represent the cleavage sites for the various
RRM1-specific siRNAs, as shown schematically in Figure 1A.
§RRM1-3 and ApoB1 are complementary in sequence to both human and mouse target genes.
Accession numbers: RRM1, NM_001033.3; LMNA, NM_005572.3; HMBS, NM_000190.3; ApoB, NM_009693.2; Polr2a, NM_009089.2. Amplicon sizes: RRM1(A): 114 bp;
RRM1(B): 127 bp; RRM1(C): 79 bp; LMNA: 139 bp; HMBS: 65 bp; ApoB1 site 107 bp; ApoB external: 86 bp; Polr2a: 95 bp.
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Page 2 of 7[13]. RNA, tumour and cell samples were all stored at
-80°C, whilst cDNA was stored at -20°C. Positive con-
trols for RT-qPCR using cDNA prepared from an A549
in vitro culture showed % CV of < 1.1 for all human pri-
mer sets between assays, whilst intra-assay variation was
< 1% for human primers, and < 2% for mouse primers.
MBRACE
5’-RLM-RACE was performed using the GeneRacer kit
(Invitrogen) with the manufacturer’si n s t r u c t i o n sm o d i -
fied as previously described [12]. The first round
5’RACE reaction product (1 μl) was used as a template
for the MBRACE reaction [12] using the FastStart Taq-
Man
® Probe Master (Roche) and primers and probes at
the following concentrations: 180 nM MB-R, 3.6 μM
MB-F and 250 nM molecular beacon probe (all specific
for the target gene cleavage site). Reactions were run on
a LightCycler 480 as described [12].
Tumour models
A549 or Hepa 1-6 cells grown in vitro were detached
from flasks with trypsin, and the enzymatic reaction was
stopped by the addition of fresh culture medium con-
taining FBS. After two washes with PBS, the cells were
resuspended in PBS at a final density of 8 × 10
7 cells/ml
(A549 cells) or 5 × 10
6 cells/ml (Hepa1-6 cells). Using a
26-gauge needle, groups of five CD1 nude mice were
injected subcutaneously on the flank with 100 μlo ft h e
cell suspension. When tumours reached 50-100 mm
3 in
size, they were twice injected (24 h apart) with 25 μg
siRNA in 50 μl saline; tumours were excised as
described (12). The effect of intratumoural injection on
RRM1 or ApoB mRNA levels was assessed by real-time
RT-qPCR 24 h after the second injection.
Results and Discussion
RRM1 reduction measured by RT-qPCR following
intratumoural siRNA administration is primer-pair specific
In a previous screen we identified RRM1 as a potential
target for siRNA-based cancer therapy [11]. Three
different siRNAs (RRM1-1, -2 and -3) induced signifi-
cant knockdown of RRM1 mRNA and protein in A549
cells in vitro, leading to growth inhibition and the
induction of apoptosis [11]. Furthermore, transfection of
A549 cells with RRM1-2 prior to implantation into
nude mice markedly inhibited tumour growth [11]. Hav-
ing observed growth inhibitory effects both in vitro and
in vivo following RRM1 knockdown in tumour cells, we
then assessed the ability of siRNAs RRM1-2 and RRM1-
3 to silence RRM1 mRNA via intratumoural injection of
siRNAs into pre-existing subcutaneous xenografts.
These siRNAs were shown to be equally potent with
IC50 values in vitro of approximately 20 pM [11,14].
Tumours were twice injected (24 h apart) with 25 μgo f
RRM1-2 or RRM1-3 siRNA in 50 μln o r m a ls a l i n ea n d
excised 24 h after the second injection. RNA was iso-
lated and RRM1 expression analysed by RT-qPCR using
two different primer pairs (RRM1-B and RRM1-C in
Figure 1).
As seen in Figure 2, measurement of an apparent
change in mRNA levels was dependent on location of
the primer pair in relation to the siRNA target site
(shown schematically in Figure 1). Primers flanking the
RRM1-2 siRNA target site (RRM1-B) showed an appar-
ent reduction of RRM1 mRNA of up to 60% in tumours
injected with RRM1-2 siRNA, whereas little knockdown
was observed in tumours injected with RRM1-3 siRNA
( F i g u r e2 A ) .C o n v e r s e l y ,t h eu s eo fap r i m e rp a i rf l a n k -
ing the RRM1-3 site (RRM1-C) in real-time RT-qPCR
showed a much greater apparent reduction in tumour
RRM1 mRNA levels in tumours injected with RRM1-3
siRNA (Figure 2B). However, the use of primer pair
RRM1-A, generating an amplicon upstream of both
RRM1-2 and RRM1-3 target sites resulted in measure-
ments of RRM1 mRNA levels that did not differ from
control siRNA-injected tumours (data not shown).
These results suggested that the knockdown was non-
specific, and this was further confirmed using a Molecu-
lar Beacon RACE assay, MBRACE, [12] specific for the
cleavage point of either RRM1-2 or RRM1-3 siRNAs.
Cleavage of RRM1 mRNA was detected with cDNA pre-
pared from RNA isolated from A549 cells transfected
with either RRM1-2 and RRM1-3 siRNA, but despite
the significant knockdown detected by RT-qPCR in the
in vivo study (Figure 2) there was no detection of speci-
fic products of siRNA-mediated knockdown in injected
tumours (Figure 3). Similar results were observed when
Hepa1-6 tumours were injected with ApoB-o rRrm1-
specific siRNA. The ApoB1 siRNA used was previously
shown to silence ApoB effectively in vitro,a sw e l la sin
vivo following hydrodynamic tail-vein injection [12].
After intratumoural injection, however, an apparent
reduction in the ApoB or Rrm1 mRNA was observed
only when the primers flanked the target site (Figure 4).
1 3234
RRM1 
5’UTR 3’UTR 
RRM1-1 RRM1-2  RRM1-3 
RRM1-A  RRM1-B RRM1-C 
RT-qPCR primer locations 
siRNA target sites 
Figure 1 Schematic representation of RRM1 mRNA, showing
siRNA target sites and primer pairs. Red arrows indicate siRNA
target sites and PCR primers are represented by curved arrows.
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Page 3 of 7The presence of siRNA compromises downstream
reactions
The apparent knockdown of RRM1/Rrm1 in tumours
following intratumoural injection of siRNA was found to
relate to the primer pair used in real-time RT-qPCR, in
contrast to the similar levels of knockdown measured in
vitro after transfection with three different siRNAs, irre-
spective of the primer pair used in RT-qPCR. This sug-
gested that the residual siRNA was interfering with
subsequent steps in the analysis, perhaps explained by
the concentration of siRNA in the RNA isolated in each
system. The method of RNA isolation used in this study
involves binding the RNA to a size selection column,
which should exclude small RNAs less than 90 bp.
However, miRNAs have been isolated using this proce-
dure [15] suggesting that the columns only reduce, but
do not exclude, small RNAs.
In the in vitro transfection, an siRNA concentration of
10 nM is the equivalent to ~80 ng per well in a 24-well
plate. If one assumes cells take up half of the siRNA
used in the transfection (and minimal degradation
occurs during the 24 h transfection period), the siRNA
component of the RNA isolated from the cells (around
10 μg) is less than 1% of the total (80 ng siRNA in ~10
μg of cell-derived total RNA). In contrast, 25 μgs i R N A
injected twice into a tumour with a volume of 50 mm
3
and yielding 50 μg total RNA is likely to be a much
greater proportion of the isolated RNA and has the
potential to interfere with downstream applications.
Further adding to the potential for co-purification is the
use of Stealth-modified siRNA duplexes, which have
chemical modifications imparting resistance to nucleases
and stability in serum.
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Figure 2 Apparent knockdown of RRM1 mRNA measured by
RT-qPCR following intratumoural injection of siRNA. A549
xenograft tumours were injected with PBS, RRM1-2, RRM1-3 or non-
targeting siRNA (81c) (n = 5). RRM1 mRNA was measured by real-
time RT-qPCR. PCR was carried out with primers flanking the RRM1-
2 (RRM1-B, shown in (A)) or RRM1-3 site (RRM1-C, shown in (B)).
A  B  RRM1-2 target  RRM1-3 target 
in vitro cDNA  
positive controls 
in vivo samples  
negative controls  
in vitro cDNA  
positive control 
in vivo samples  
negative controls  
Figure 3 Detection of siRNA-mediated cleavage of RRM1 mRNA following in vitro transfection or intratumoural injection with RRM1 siRNAs.
A549 xenograft tumours were injected as described in Figure 2 with RRM1-2 siRNA (A) or RRM1-3 siRNA (B). In vitro positive control: cDNA from A549
cells transfected with 1 nM RRM1-2 or RRM1-3 siRNA; samples were tested in triplicate, one single amplification curve is shown per sample for clarity.
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Page 4 of 7To explore this possibility, we investigated the effect
of adding siRNA to the real-time qPCR step (Figure 5).
We used cDNA reverse-transcribed from RNA isolated
from the tumour of a PBS-treated mouse as template
for real-time qPCR, and measured the effects of adding
increasing amounts of various siRNAs. As shown in Fig-
ure 5A, PCR with the addition of RRM1-2 siRNA at
high (50 to 200 μM) concentrations led to inhibition of
RT-qPCR, but only when the primer pair flanking the
target site (RRM1-B) was used. In contrast, there was no
effect on the RRM1 mRNA levels measured in the pre-
sence of either RRM1-3 or ApoB-specific siRNAs.
We also assessed whether siRNA was able to interfere
with the reverse transcription step of real-time RT-qPCR.
We again used RNA isolated from the tumour of a PBS-
treated mouse as template, but here we added increasing
concentrations of siRNA or single-stranded RNA to the
RNA template in the reverse transcription reaction.
RRM1-3 or control siRNA, as well as the single-stranded
sense or antisense strands of the RRM1-3 siRNA were
added at the concentrations indicated. As seen in Figure
5B, introducing either the RRM1-3 siRNA duplex or anti-
sense strand led to reduced detection of RRM1 message
when RRM1-3 flanking primers (RRM1-C) were used. In
contrast, introducing RRM1-2 siRNA or RRM1-3 sense
strand had no effect on measurements of RRM1 levels.
When the primer pair flanking the RRM1-1 site (RRM1-
A) was used, no interference was observed (data not
shown). Lastly, we added RRM1-2 or RRM1-3 siRNA
(25 μg) to tumours prior to RNA extraction, and
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Figure 4 Apparent knockdown of mRNA in mouse tumours is primer pair-specific. Hepa 1-6 tumours (n = 5) were injected with the
indicated siRNAs and ApoB (A, B) or Rrm1 (C, D) mRNA levels measured by real-time RT-qPCR using primers flanking the siRNA target site (B, D)
or outside this region (A,C). mmApoB is an inactive mismatched siRNA control; 81C is a control with no known mRNA target, pbs - PBS-injected
tumours.
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Page 5 of 7evaluated mRNA measurements with different primer
pairs (Figure 5C). Only when a flanking primer pair was
used with template containing the corresponding siRNA
was an apparent knockdown detected; no effect was seen
with the RRM1-A primer pair, which is located upstream
of both RRM1-2 and RRM1-3 sites.
Conclusions
Following intratumoural injection of RRM1-specific siR-
NAs, the apparent reduction of RRM1 transcript levels
was found to be a function of the primer pair used. Sub-
sequent in vitro investigations suggested that this most
likely resulted from interference with reverse transcrip-
tion, and to a lesser extent real-time qPCR, caused by
siRNA co-purified in the RNA isolation. These data sug-
gest that primers flanking the siRNA target site should
be avoided in studies of siRNA in vivo, especially when
large amounts of siRNA are used.
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